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PLATELET INDUCTION OF MONOCYTE TO DENDRITIC CELL
DIFFERENTIATION. Tyler S. Durazzo, Robert E Tigelaar, Carole L Berger, Michael
Girardi, Richard L Edelson. Department of Dermatology, Yale Cancer Center, Yale
University, School of Medicine, New Haven, CT

We hypothesized that activated platelets induce monocyte-to-dendritic cell (DC) differentiation.
The aims of this study were to: (1) determine the role that platelets play, if any, in the signaling of
monocyte to DC differentiation; (2) determine the mechanism of action by which platelets induce
monocyte-to-DC differentiation. (3) Use this knowledge to advance cancer immunotherapy.

To achieve these ends: (1) parallel-plate flow chambers were designed to deliver monocytes a
controlled level of platelet exposure, with phenotype and genotype assessed following overnight
incubation; (2) blocking antibodies and proteins were used to assess for the significance of
particular monocyte-platelet interactions in the mechanism; (3) additional experiments and
mathematical modeling was performed to extrapolate our new mechanistic knowledge to enhance
extracorporeal photochemotherapy (ECP), an immunotherapy in clinical use.

Results showed direct correlation between platelet exposure and level of DC differentiation
following overnight incubation (p < 0.0001). A detailed mechanism was determined involving pselectin and other proteins expressed by activated platelets. This mechanistic knowledge permitted
intelligent modification of ECP.
We conclude that platelets induce monocyte to DC differentiation. The rapidity and efficiency of
this induction suggests the possibility that this is a physiologic mechanism employed in-vivo for
DC differentiation. Possible exploitation of this mechanism may prove beneficial in cancer
immunotherapy.
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1. INTRODUCTION
1.1 Overview
Due to high response rates and an excellent safety profile, extracorporeal
photochemotherapy (ECP) is widely used for immunotherapy in patients with leukemic
cutaneous T-cell lymphoma (CTCL), graft versus host disease, and organ transplant
rejection [1]. Recently, it has been reported that ECP induces a high percentage of
processed monocytes to enter the dendritic cell (DC) differentiation pathway, within a
single day of treatment [2]. Despite intense research, the mechanism by which ECP
induces this differentiation has remained elusive.

Dendritic cells (DC) are the most potent antigen presenting cells in the human body,
orders of magnitude more powerful than any other cell type know [3]. Their
physiologic role has proven to be central to immune function. Located at the interface
between innate and adaptive immunity, DC orchestrate the immune system’s response
via their influence on CD4+ T-cells, CD8+ T-cells, and other effector cell types [4].
Their central role in the immune system has recently placed them at the forefront of
cancer immunotherapy [5-7].
We investigated the mechanism by which ECP induces monocyte-to-DC
differentiation. The efficiency and rapidity of this cellular conversion, occurring
without addition of exogenous growth factors, suggests that the manner in which ECP
induces monocytes to differentiate into DC may result from the co-opting of a normal
physiologic mechanism controlling DC maturation. Hence, elucidation of the
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molecular basis for ECP’s influence on monocytes may provide important clues about
in-vivo DC generation.

To investigate this phenomenon, we developed an ECP model which could be
visualized with digital microscopy and therefore permit direct visualization of the
cellular components and flow dynamics involved. We report in this thesis that
activated platelets induce monocyte-to-DC differentiation under flow conditions
mimicking those found in post-capillary venules.

1.2 Physiologic Dendritic Cell Development
Relatively little is known regarding DC development in comparison to other cells of
haemotopoietic origin. Based on evidence mainly from mouse models, current theories
propose that most DC develop in vivo from hematopoietic stem cell-derived
progenitors with both lymphoid and myeloid-restricted differentiation potential [8].
One common precursor is believed to give rise to monocytes, macrophages, and
dendritic cells in the bone marrow. Furthermore, some monocytes possess the
potential, after leaving the bone marrow, to differentiate under inflammatory conditions
into both DC and macrophages [9]. It is this DC differentiation from peripheral blood
monocytes which is of particular relevance to this thesis.

Much work remains to be done in terms of elucidating the in-vivo factors responsible
for inducing peripheral blood monocyte-to-dendritic cell differentiation. Part of the
difficulty in the field has stemmed from the complexity and varying nature of
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monocyte populations, as well as inconsistencies among studies done in-vivo versus invitro [9-11]. These inconsistencies, however, have drawn attention to the likelihood
that physiologic monocyte-to-DC differentiation in-vivo is dependent on both intrinsic
monocyte potential as well as factors acting upon the monocyte.

There exists clear evidence that human blood monocytes are heterogeneous: expressing
different proteins, responding differently to various stimuli, and producing different
products [11]. In vivo studies have provided evidence that two monocyte
subpopulations, Ly6C+ and Ly6C-, apparently have separate potentials, regardless of
the factors acting upon them [12-15]. Ly6C+ monocytes appear capable of
differentiation into DC, Langerhans cells, inflammatory macrophages, or myeloidderived suppressor cells; Ly6C- monocytes appear to have the potential to differentiate
into alveolar macrophages [9].

In vitro studies have provided evidence for environmental factors that contribute to DC
differentiation. Exposing both human and mouse monocytes to suprapharmacologic
doses of IL-4 and GM-CSF for long periods in culture results in differentiation into
DC, regardless of the monocyte subset [10, 16, 17]. Furthermore, addition of TGF-1
to the cultures results in Langerhans cell differentiation [18]. In contrast, addition of
IL-6 to the same cultures results in macrophage, not DC, differentiation [19].
Exposing monocytes to M-CSF in vitro also results in macrophage differentiation [18].
Monocytes cultured with M-CSF can be further influenced to differentiate into either
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M1 or M2-subtype macrophages by addition of either IFN-gamma or IL-4,
respectively [20, 21].

It is clear that in vitro, monocyte differentiation is influenced heavily by the cytokine
environment, albeit only to suprapharmacologic doses. How to precisely extrapolate
these findings to physiologic in-vivo mechanisms of monocyte-to-DC differentiation
remains to be determined. Additionally, functional differences between those in-vitro
generated cells and their in-vivo counterparts have not yet been fully explored. As
outlined in section 1.4, DC generated using in-vitro suprapharmacologic cytokines
have been relatively unsuccessful at reaching the theoretical potential DC posses in
cancer immunotherapy.

1.3 Extracorporeal Photochemotherapy (ECP)
ECP is the first FDA approved cellular immunotherapy, originally introduced in 1987
for the treatment of patients with severe CTCL [22]. Since its initial introduction, the
therapy’s clinical application has been extended to include successful treatment of
patients with chronic graft-versus host disease (GVHD), and prevention of organ
transplant rejection [23, 24]. The therapy’s high clinical success rate in otherwise
therapeutically resistant situations, in addition to its low toxicity [25], has led to the
therapy being used over 1.5 million times in over 150 centers throughout the world.
Despite the therapy’s clinical success, its precise mechanism of action has remained
unknown. Recent studies have shown that the therapy causes monocyte-to-DC
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differentiation, however the mechanism responsible for this induction remains
unidentified [1, 2].

The therapy consists of collecting a small number (<10%) of a patient’s lymphocytes
via leukophersis of peripheral blood. 8-methoxypsoralen (8-MOP) is then added to
these collected cells (suspended in plasma), followed by passage of the cells through a
1-mm space located between two transparent plastic plates. While the cells are passed
through the transparent plates, they are irradiated with UVA energy, causing 8-MOP to
become activated and covalently crosslink thymine bases of DNA [26]; this
crosslinking causes a fraction of cells to undergo apoptosis. The therapy is completed
by reinfusing the treated cells into the patient.

Interestingly, the treatment is conducted identically as described for both CTCL (a
cancer expected to respond to immunostimulation), as well as GVHD (a condition
expected to positively respond to immunosuppression). The seemingly paradoxical
ability of the same treatment to invoke immunotherapeutic responses at both ends of
the spectrum is consistent with ability of the treatment to generate fully functional
dendritic cells; dendritic cells are well known for their physiologic capacity to
orchestrate immune responses in either direction, depending on stimuli encountered in
the body [4].

The DCs generated by ECP have been shown to be functionally capable of processing
and presenting exogenous and endogenous antigen [2]. Furthermore, microarray
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analysis have shown that ECP-processed monocytes show expression profiles
consistent with functional DC, with up or down regulation of more than 1100 genes
[2]. Dramatic increases in surface expression of proteins critical to DC function have
also been documented in DC generated by ECP. Interestingly, all these changes
described occur in less than 18 hours after treatment, without the need for any
exogenous cytokines or growth factors.

The time course of DC induction, the non-requirement for exogenous growth factors,
and the clinical success, all suggest that the ECP may be recapitulating a physiologic
mechanism of DC generation. Therefore, study of ECP’s unknown mechanism of DC
induction may provide insight into physiologic principles of DC generation.
Furthermore, if these principles are uncovered, improvements to the ECP system may
be made which allow for better control, greater influence, and higher DC yields.

1.4 Dendritic Cells and Cancer Immunotherapy
DCs’ central role in the immune system has placed them at the forefront of cancer
immunotherapy. Recent years have seen an increase in attempts at generating DC for
the purpose of inducing clinical immunity against various cancers [5-7]. These
therapeutic protocols have thus far not lived up to the theoretical potential DCs
possess. One potential explanation for the relative lack of successes is that the vast
majority of protocols are based on generating DC from monocytes by administering
suprapharmacologic doses of cytokines and growth factors, for instance, CM-CSF and
IL-4 for 6 days, followed by TNF-alpha for 2 days [27]. As stated earlier, the
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functional correspondence among DC generated in this manner in comparison to those
generated physiologically is unknown. A better understanding of physiologic
principles of DC generation may allow for their theoretical potential of generating
cancer immunity to be better realized.

1.5 Platelets and Immunobiology
Platelets are well recognized for their main role in thrombus formation and
maintenance of hemostasis. However, a comparatively recent body of literature has
revealed an additional relevant function in immunobiology [28, 29].

Platelets are cell fragments derived from the cytoplasm of megakaryocytes in the bone
marrow. While only approximately 2 microns in diameter, they circulate at levels of
approximately 300,000/l in healthy individuals, making their total volume greater
than any other leukocyte subset [30]. In addition, due to physical properties of flow
dynamics in blood vessels (see Appendix A), their relatively small size places them
more proximal to the endothelium than any leukocyte population, making them ideal
for immune surveillance.

Studies have shown that inflammation within tissue leads to an imbalance of
procoagulant and anticoagulant properties of the local endothelium, resulting in platelet
recruitment and activation [29]. For instance, one of the first pro-inflammatory
cytokines released at sites of tissue infection is TNF-alpha; this molecule has been
shown to inhibit synthesis of protein C [31], an anticoagulant protein, while
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simultaneously inducing TF production on the endothelium [32]. This results in
thrombin activation and fibrin formation, which in turn recruits and activates platelets.
Interestingly, TNF-alpha concurrently causes nitric oxide (NO) release from
endothelium [33]. NO is a potent inhibitor of platelet aggregation; thus, TNF-alpha is
able to delicately recruit and activate platelets to sites of inflammation while
simultaneously preventing thrombus formation, which would likely prove detrimental
to leukocyte recruitment by limiting perfusion of the inflamed region.

Activated platelets have been found to express and secrete a number of ligands and
substances capable of recruiting and activating leukocytes, including p-selectin [29],
CD40L [34], IL-1B [35], CCL5, and CXCL4 [36]. Complex interactions among
platelets and leukocytes have been found to contribute to various immune processes,
including progression of atherosclerotic lesions [37], wound healing [38], and atopic
dermatitis [30]. While the body of literature implementing platelets in key
immunologic roles continues to mount, a role in inducing monocyte-to-DC
differentiation has not been described to our knowledge.
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HYPOTHESIS AND SPECIFIC AIMS

The initial aim of the work presented in this thesis was to determine the mechanism
behind ECP’s induction of monocyte to dendritic cell differentiation. As described in
the results section, preliminary experiments suggested a role for platelets, subsequently
leading to our main hypothesis: platelets induce monocyte-to-dendritic cell
differentiation.

The subsequent aims of the work presented in this thesis were to: (1) determine the role
that platelets play, if any, in the signaling of monocyte to dendritic cell differentiation;
(2) determine the mechanism of action in which platelets induce monocyte-to-dendritic
cell differentiation; and (3) use the mechanistic knowledge gained to intelligently
advance ECP with the hope of potentially extending its scope in cancer
immunotherapy.

14

METHODS
Statement of author’s contribution: All work composing this thesis and presented in
the subsequent sections was performed by the first author of the thesis.
Obtainment of leukocytes and platelets: All samples were acquired from young,
healthy subjects not taking medication, including aspirin, known to influence platelet
function. Samples were obtained under the guidelines of the Yale Human
Investigational Review Board. Informed consent was provided according to the
Declaration of Helsinki. Peripherial blood specimens were collected through a 19gauge needle from the antecubital vein into syringes containing heparin, then layered
on Ficoll-Hypaque (Gallard-Schlessinger, Carle Place, N.Y.). Following centrifugation
at 180g, the interface containing the mononuclear leukocyte fraction was collected and
washed twice in HBSS, then resuspended in RPMI-1640 medium (GIBCO) to a final
concentration of 5 * 106 mononuclear cells/ml. Experiments with the obtained cells
were performed within one hour of being acquired.

Preparation of Platelet-rich-Plasma: Whole blood was centrifuged at 150 g for 15
min at room temperature. The platelet-rich-plasma (PRP) layer was collected and
centrifuged at 900 g for 5 min, and the platelet pellet resuspended in RPMI 1640 to the
desired concentration.
Preparation of Parallel-Plates: Two types of parallel-plate flow chambers were used
to model the flow dynamics of ECP. Experiments involving the assessment of cellphenotype post-flow were conducted using the larger Glycotech system (Glycotech,
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Rockville, MD). This system consisted of a volumetric flow path measuring 20000 x
10000 x 254 microns (length x width x height). The bottom plate in this system was
composed of a 15mm petri dish (BD Biosciences, Durham, NC) separated by a gasket
and vacuum-connected to an acrylic flow deck, which formed the upper plate. For
experiments requiring the plates to be pre-coated with platelets, prior to assembling the
flow chamber, 20 drops of the desired concentration of PRP was placed in the center of
the petri dish and platelets allowed to settle for 20 minutes at room temperature. The
petri dish was washed with 2ml of RPMI twice, and the flow chamber then assembled.

For experiments not involving the collection and phenotyping of cells post-flow,
Vena8 biochips (Cellix Ltd, Dublin, Ireland) were used to generate laminar flow. The
volumetric flow path for a channel of the Vena8 biochips measured 20000 x 400 x 100
microns (length x width x height). Protein coating of these chips are described in the
appropriate section below.

Experiments using Parallel-Plates: In all cases, the parallel-plate flow chamber was
mounted on the stage of a phase contrast optical microscope (CK40, Olympus, Japan)
with a 10x objective. All runs were performed at room temperature. A uniform laminar
flow field was simulated by use of a syringe pump (KD Scientific, New Hope, PA)
capable of generating near-constant volumetric flow rates. The components of the
configuration were set up to minimize tubing. Prior to infusing cell suspensions
through the plates, the configuration was washed with 5 ml of RPMI at a flow rate
producing a wall shear stress of approximately 1 dyne/cm2. Cell suspensions of
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interest were then sent through the chamber at a fixed flow rate and wall shear stress
(see Appendix A).

All experiments were viewed in real time while in progress, and recorded using a DP
200 digital camera and software (DeltaPix, Maalov, Denmark) at 15.2 frames per
second. When applicable, images were analyzed using Image J software (NIH).

Overnight culture: When overnight culture was desired, cells were centrifuged and
resuspended in RPMI-1640 medium (GIBCO), supplemented with 15% AB serum
(Gemini Bio-Products) to a final concentration of 5 x 10E6 cells/ml. Cells were
cultured overnight for 18 hours in 12-well polystyrene tissue culture pates (2 ml per
well) at 37 degrees C with 5% CO2.

Immunophenotyping: Monoclonal antibodies for immunophenotyping included
CD14 (LPS receptor; monocytes), CD11c (integrin subunit; monocytes and DC), HLADR (class II MHC molecule), CD83 (DC marker), CD62p (P-selectin; activated
platelets), and CD61 (integrin subunit; platelets). Antibodies were obtained from
Beckman Coulter (CD14, CD11c, HLADR, CD83) or Sigma (CD62p, CD61) and used
at their pre-determined optimal dilutions. Background staining was established with
appropriate isotype controls, and immunofluorescence was analyzed using a FC500
flow cytometer (Beckman Coulter). Two-color membrane staining was performed by
adding the pre-determined optimal concentrations of both antibodies directly
conjugated to FITC or PE and incubating for 20 min at 4°C, followed by washing to
remove unbound antibodies. Combined membrane and cytoplasmic staining was
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performed following manufacturer’s instructions for cell fixation and permeabilization
(Intraprep kit, Beckman Coulter).

Quantitative real-time PCR: Gene expression was compared between cells exposed
during flow through the parallel plates to low (10 + 5/low power field [lpf’]) verses
high (102 + 32/lpf) levels of platelets, followed by overnight culture. Cell RNA was
isolated using RNeasy Mini Kit columns with on-column DNase I treatment
(QIAGEN). RNA yield and purity were measured using the NanoDrop ND-1000
Spectrophotometer and the Agilent 2100 Bioanalyzer. RNA was reverse transcribed to
cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Reverse transcription was carried out in a 96-well thermocycler (MJ
Research PTC-200) in the following conditions: 25°C, 10 minutes, 37°C, 120 minutes,
85°C, 5 seconds. TaqMan real-time PCR was used to detect transcripts of DC-LAMP,
CD40, ADAM Decysin, Lox1, CCR7, CD80, CD83, CD86, FPRL2, and GPNMB.
Primers and probes for each sequence were obtained as inventoried Taqman Gene
Expression Assays (Applied Biosystems). HPRT1 was used as a reference gene.

Co-cultures of Platelets with Monocytes: Experiments involving co-cultures of
monocytes with additional platelets were performed as described in the Overnight
Culture section, with a few necessary modifications. Following Ficoll-Hypaque
separation, mononuclear cells were resuspended in 30% AB serum/RMPI to a final
concentration of 10 x 106 cells/ml, of which 1ml was allocated to each well of a 16-
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well plate. An additional 1ml or platelets (suspended in RPMI, at 2x the desired endconcentration) or RPMI without platelets was then added to each well. To activate
platelets, 500 l containing 2 units of thrombin was added to half the wells, and 500 l
of RPMI was added to the others to balance volume. Cells were then incubated as
described previously.

Platelet Adhesion Studies: Platelet adhesion experiments were performed using the
Vena8 flow chamber described above. Fibrinogen and fibronectin (Sigma) were
dissolved in PBS to a final concentration of 200 g/ml. Channels of the Vena8 chips
were incubated at room temperature in a humidified chamber for 2 hours with the
protein solution, autologous plasma, or PBS alone. The channels were washed with 5x
the volume RPMI. Platelet-rich-plasma was then perfused through the protein-coated
channel at the indicated shear-stress, held constant. For each channel, still images were
acquired exactly 90 seconds into the experiment at 4 pre-defined low power fields
located along the flow path (fields were centered at 2500, 7500, 12500, and 17500
microns from the start point of infusion).

Some experiments involved pre-treating platelet-rich-plasma (PRP) with protein
fragments prior to infusion through the channels. Small RGD peptides containing the
amino-acid sequence Arg-Gly-Asp-Ser, DRG peptides containing the amino-acid
sequence Ser-Asp-Gly-Arg, or fragment 400-411 of fibrinogen containing the aminoacid sequence His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val, were incubated at
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a concentration of 2mM with PRP for 20 minutes at room temperature. The PRP was
then perfused through the channels as previously described.

Receptor-Ligand Studies: Same protocol followed as described in appropriate
sections above, with a few necessary modifications. Vena8 platelet-coated channels
were pre-treated with either 40 g/ml anti-p-selectin (R&D Systems) or 40 g/ml of an
isotype control for 30 minutes at room temperature, then washed with 5x the volume
RPMI. Mononuclear cell suspensions were pre-treated with either RGD peptides or
DGR peptides at a concentration of 2.5 mM. Video samples lasting 400 frames (26.3
seconds) were recorded 60 seconds after commencement of flow using a lower power
field of view spanning 400 microns and centered at 7500 microns from the flow start
point.

Studies aimed at assessing the protein conformation of beta-1 integrins were conducted
using the Glycotech flow chamber. 15mm platelet-coated petri dishes (as described in
section above) were pre-treated with 40 g/ml p-selectin or an isotype control for 20
minutes at room temperature, then washed with 5x the volume RPMI. Immediately
following perfusion through the platelets, cells were immunophenotyped with antiCD29 HUTS-21 (BD Biosciences), an antibody that specifically binds to the active
conformation of 1 integrins.

Full-Scale-ECP: Leukocytes were collected as described above. A full-scale ECP
exposure plate (Therakos) was connected in series to a peristaltic pump (MasterFlex
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LS), permitting the repetitive circulation of cell-suspensions through the plate for at
room temperature. When indicated, ECP exposure plates were pre-incubated with
platelet-rich-plasma for 15 minutes prior to the infusion of cell-suspensions. Cell
suspensions were circulated for 45 minutes at volumetric flow rates of either 100
ml/min or 24.2 ml/min, followed by 30 seconds at 280 ml/min and collection (see
Appendix A). Cells were incubated overnight and phenotyped as described in the
sections above.
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RESULTS
Monocytes in flow transiently interact with immobilized platelets
ECP was initially developed as a means to enable extracorporeal chemotherapeutic
exposure of pathogenic leukocytes to ultraviolet A (UVA)-activated 8methoxypsoralen (8-MOP), a DNA-cross-linking drug. Therefore, ECP involves the
flow of leukapheresed blood between large transparent plastic parallel-plates separated
by 1 mm. To permit detailed analysis of the flow dynamics involved during ECP,
independent of UVA/8-MOP exposure, we reproduced the flow conditions of ECP
using miniature parallel plates with surface area of only 0.8 mm2, separated by 100
microns. This model permitted visualization using digital microscopy. Studies using
the model (see Supplement 1 for video) revealed the following sequence occurring in
ECP: initial adherence of platelets from the flow stream to the plastic plate, followed
by transient binding of passaged monocytes to the immobilized platelets.

DC induction correlates with the number of monocyte-platelet interactions
Based on the initial qualitative observations described above, platelets were
hypothesized to contribute substantially to ECP’s induction of DC. To test the
influence of platelets on monocyte-to-DC differentiation, monocytes were passed
between parallel plates pre-coated with autologous platelets at low (10 + 5/low power
field [lpf]), medium (44 + 20/lpf), and high (102 + 32/lpf) densities. The number of
monocyte-platelet interactions per unit time increased in proportion to augmented
density of platelets (see Supplement 2 for videos). An average of 52.3 + 15 platelet-
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monocyte interactions per lpf per second were observed with the high-density plate,
dropping to 18.3 + 14 and 3.4 +1 interactions per second with the medium and lowdensity plates, respectively (Figure 1A). Following overnight incubation, a correlation
was found between frequency of platelet-monocyte physical interactions in the plate
and the proportion of cells expressing the DC phenotype (Figure 1B). As the number
of platelet-monocyte interactions increased, so too did the proportion of cells
expressing markers consistent with DC differentiation, membrane HLA-DR and CD83:
an average of 14.2% of monocytes exposed to the high-density platelet-coated plate
were HLA-DR+/ CD83+ after overnight incubation, in comparison to 4.9% and 0.8%
exposed to plates coated with medium and low levels of platelets, respectively.
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Figure 1. Effect of platelet density on number of platelet-monocyte interactions and
subsequent monocyte phenotype. Monocytes were passed through parallel plates
coated with platelets at low, medium, or high density. (A) The number of plateletmonocyte interactions increased substantially for plates coated with higher densities of
platelets. (B) After overnight incubation, monocytes which were exposed to high
levels of platelets were significantly more likely to develop a phenotype consistent
with DC differentiation, as assessed by expression of membrane CD83 and HLA-DR
(high versus medium or low density: p <0.0001; medium versus low density: p <
0.005). lpf, low power field.
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Monocyte exposure to platelets results in changes in gene expression
To supplement the described changes in monocyte phenotype observed following
platelet exposure, RT-PCR was performed to assess for changes in gene expression.
Monocytes were passed through parallel plates coated with high or low densities of
platelets as described in the previous section. Following overnight incubation, RNA
was extracted and RT-PCR performed to determine level of expression for 10 genes
associated with DC (Figure 2). CD40, a costimulatory molecule with known
expression on mature DCs [39], was found to be upregulated by over 567% in
monocytes exposed to high densities of platelets relative to monocytes exposed to low
levels. LAMP3, a marker specific to DC differentiation [40], was upregulated by
398%. CD80, a costimulatory molecule known to be upregulated upon APC activation
[41], was found upregulated by 220% in monocytes exposed to high levels of platelets.
CCR7, a chemokine receptor known to play a role in DC migration to lymphoid
organs, was upregulated by 376%. LOX1, CD83, CCR7, and ADAM Decysin, all
genes associated with DC [2], were upregulated in the monocytes exposed to high
levels of platelets. FPRL2, GPNMB, and CD86 were all downregulated in monocytes
exposed to high levels of platelets. FPRL2 is a receptor that when activated is known
to inhibit DC maturation [42]; GPNMB is a protein involved in decreasing cytokine
production [43]; CD86 is a costimulatory molecule expressed by APCs.
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Figure 2. Gene expression following exposure to platelets. Monocytes were exposed
to high or low levels of platelets in flow. Following overnight incubation, cells were
assessed for differences in gene expression using RT-PCR. Figure shows gene
expression changes in monocytes exposed to high levels of platelets relative to those
exposed to low levels. Seven genes associated with DC-differentiation and/or function
were found to be upregulated, while three were downregulated. Of the genes
downregulated, GPNMB and FPRL2 have known functions in decreasing cytokine
production and inhibiting DC maturation, respectively. Of the genes upregulated, all
have either pro-immune functions or miscellaneous roles in DC biology. See text for
specific description of genes.

DC induction did not occur under static conditions in the presence of platelets
Platelets could potentially influence monocytes through direct receptor-ligand
interaction, or via cytokines and other secreted mediators. Furthermore, it is well
known that formation of receptor-ligand bonds in flowing systems is influenced by
shear forces [44, 45]. Accordingly, we next tested whether flow dynamics were
required for platelet-dependent induction of monocytes in this system.

To determine

whether the platelet induction of monocyte-to-DC differentiation requires flow
dynamics, we tested the role of platelets under static conditions. Monocytes were co-
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cultured with low (<50,000/mm3), medium (100-200,000/mm3) and high
(>400,000/mm3) concentrations of platelets, with platelets in either an inactive or
active state (induced by the addition of thrombin). After overnight incubation in static
conditions (shear stress = 0), we found that neither activated nor non-activated platelets
were capable of inducting DC differentiation of monocytes in the absence of flow
(Figure 3).

Figure 3. Platelet influence on monocyte differentiation in static conditions.
Monocytes were co-cultured for 18 hours with low, medium, or high concentrations of
platelets in static conditions lacking flow. Under these conditions, there was no
observable platelet influence on DC differentiation; all conditions resulted in low,
basline levels of cells expressing DC markers. Furthermore, activating platelets with
thromin in culture (blue line) did not cause a discernable difference in monocyte
differentiation relative to those cultures containing plaetlets not activated by thrombin
(red line).

27

Platelets suspended in flow bind to serum proteins adsorbed onto the plate
A range of proteins abundantly present in plasma, including fibronectin and fibrinogen,
are well known to adsorb onto glass and plastic surfaces; we therefore assessed the
contribution of plastic-adherent plasma proteins on platelet adhesion and activation.
Plastic parallel plates were pre-coated with either fibrinogen, fibronectin, plasma, or
saline. Unactivated platelets were then passed through at shear rates producing wall
shear stresses ranging from 0.2 to 6.0 dyne/cm2 (encompassing the relevant ECP range,
see Appendix A). The highest concentrations of platelets adhered to plates coated with
fibrinogen (Figure 4a). Adhesion to fibronectin-coated, plasma-coated, and uncoated
plates was observed as well, but to a significantly lower extent at all shear levels below
2.5 dyne/cm2 (p < 0.01). In the absence of flow, platelet adherence was equivalent on
all protein substrates (data not shown).
Both fibrinogen and fibronectin contain segments with the amino acid sequence
arginine(R)-gylcine(G)-aspartate(D), RGD. RGD segments are well-known to interact
with many integrin receptors, particularly the I/A domain of beta subunits, which are
exposed when the integrins are in the active conformation [46]. In experiments using
fibrinogen-coated plates, platelet adhesion was not significantly altered by preincubation of platelets with RGD peptides; however, adhesion was significantly
decreased (p < 0.05) by pre-incubation of platelets with peptide fragments
corresponding to amino acids 400-411 of fibrinogen, the gamma component of the
protein (Figure 4b, left panel). In experiments using fibronectin-coated plates, preincubating platelets with RGD peptides decreased adhesion significantly (p < 0.001),
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while pre-incubating platelets with peptide fragments corresponding to amino acids
400-411 of fibrinogen had no effect (Figure 4b, right panel). Interestingly, it should be
noted that unlike the I/A domain of integrins, which is known to interact with RGD
domains of proteins, the region of the intergrin found to interact with the gamma
component of fibrinogen is exposed in the intergrin’s inactive state. Therefore, this
data suggests that unactivated platelets in flow bind to the gamma-component of
fibrinogen-coated plates. The potential for platelets in the unactivated state to bind
fibrinogen may explain the greater level of platelet adhesion seen on fibrinogen coated
plates noted in the previous paragraph.
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Figure 4. Plasma protein influence on platelet adhesion to plastic plates. (A) Platelets
were passed through plates coated with fibrinogen (blue), plasma (red), fibronectin
(purple), or RMPI (green) at the shear stress level indicated by the x-axis. Platelets in
flow adhered optimally to fibronectin. For all proteins, platelet adhesion occurred
maximally between 0.5 and 1.0 dyne/cm2. (B) Platelets were pretreated with either
RGD fragments (+RGD) or gamma fragments (+Gamma) and their subsequent
adhesion to fibrinogen (left panel) and fibronectin (right panel) was assessed. Platelet
binding to fibrinogen was decreased by gamma fragments (p < 0.05), while binding to
fibronectin was decreased by RGD peptides (p < 0.001). lpf, low power field.
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Platelets are activated by adhesion to the plate
Platelets physiologically circulate in an inactive state, with an array of proteins
contained in intra-cellular granules, upon encountering stimuli such as damaged
endothelium or thrombin, platelets become activated and translocate these intracellular
proteins to the plasma membrane almost instantaneously [47]. We postulated that
platelet adhesion to the plastic plate/absorbed proteins caused platelet activation similar
to that caused by well-known stimuli. To test this hypothesis, we assessed surface
expression of p-selectin, a well-known marker of platelet activation, before and after
adhesion. Prior to adhesion, 6 + 3% of platelets were found to express p-selectin, with
a mean fluorescence intensity (MFI) of 12.4 + 6.9; following adhesion, p-selectin
positivity increased to 64 + 13% (MFI 98.2 + 14). The positive control consisted of
platelets activated with thrombin and was found to be 71 + 18 % p-selectin positive
(MFI 108.3 + 23). Since the clinical ECP procedure can often last longer than 60
minutes, expression of p-selectin was further assessed at 30, 60, and 90 minutes
following adhesion. P-selectin expression was found to remain stable at all time
points, with 72 + 11% of platelets p-selectin positive 90 minutes after adhesion,
indicating that platelets remain in an active state for the duration of the clinical
procedure. Similar trends were found in assessment of IIb-3, a fibrinogen-binding
integrin, with surface expression of this protein increasing significantly following
adhesion (data not shown).
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Monocytes interact with p-selectin and RGD-containing ligands expressed on
activated platelets
The monocyte-platelet interactions observed on video were divided into two categories:
(1) short-acting, defined as contact occurring for less than 3 seconds (48 frames), and
(2) long-acting, defined as contact longer than 3 seconds, including stable binding.
Since we previously determined that the platelets in the ECP system were in an
activated state, and activated platelets express an array of proteins including p-selectin
and RGD containing proteins (e.g.fibronectin, fibrinogen, and vitronectin), we sought
to determine the involvement, if any, of these proteins in either short or long-duration
interactions. Plastic plates were pre-coated with platelets, and 4 conditions tested: (1)
platelets pre-treated with an irrelevant isotype control, and monocytes untreated
(P+RGD+); (2) platelets pre-treated with an irrelevant isotype control, and monocytes
pre-incubated with RGD peptides (P+RGD-); (3) platelets pre-treated with anti-pselectin, and monocytes untreated (P-RGD+); (4) platelets pre-treated with anti-pselectin, and monocytes pre-treated with RGD peptides (P-RGD-). Pre-treating
monocytes with RGD peptides should result in a decreased in the number of free RGDrecognizing receptors available to interact with RGD-containing proteins expressed by
the platelets. Thus, the four conditions tested represent every permutation of potential
interaction with 2 platelet ligands: p-selectin and RGD-containing-proteins. As shown
by Figure 5, both short-acting and long-acting interactions were maximal when neither
RGD nor p-selectin were blocked (P+RGD+), and the level of interaction in all other
conditions was expressed as a percentage of this maximum. Blocking with anti-pselectin alone (P-RGD+) resulted in a decrease of both short and long monocyte-
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platelet interactions to almost zero (p < 0.01, Figure 6, Supplements 3 for video). In
contrast, blocking RGD along (P+RGD-) did not significantly alter the number of
short-duration interactions, but decreased the long-duration monocyte-platelet
interactions by 44% (p < 0.05, Figure 6). Blocking both p-selectin and RGD
simultaneously (P-RGD-) resulted in a pattern similar to that seen when only p-selectin
was blocked, with both long and short duration interactions reduced to near zero.
The logical conclusions which are most appropriate, based on the pattern of
interactions observed in each of the four conditions, are as follows: (1) p-selectin is
predominantly responsible for the short-duration interactions; (2) RGD-containing
proteins expressed by the platelet are involved in long-duration interactions, but not
short-duration interactions; (3) monocyte interaction with p-selectin must occur
upstream of monocyte interaction with RGD-containing proteins expressed by
platelets. Conclusion (3) immediately above is based on the observation that
conditions of P-RGD+ decreased both short and long duration interactions to near zero,
while P+RGD- conditions only influenced (decreased) long-duration interactions. If
there was no sequentiality involved in the interactions, then given that P+RGD- only
resulted in a decrease in long-duration interactions, conditions of P-RGD+ should have
produced similar results to P+RGD+ in terms of long-duration interactions.
Furthermore, the ordering of the interactions, i.e. that p-selectin acts upstream of RGDinteractions, is apparent by the finding that conditions of P+RGD- only influenced long
duration interactions, while conditions of P-RGD+ produced similar results to those of
P-RGD-.
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Figure 5. Proteins involved in platelet-monocyte interactions. Monocytes were passed
between platelet-coated plates at a wall shear stress of 0.5 dyne/cm2 under the
conditions indicated by the x-axis: platelets were either pretreated with anti p-selectin
(P-) or an isotype control (P+); monocytes were either pretreated with RGD peptides
(RGD-) or a control fragment (RGD+). Platelet-monocyte interactions were quantified
under each set of conditions using digital microscopy, and are expressed in the figure
as a fraction of the maximum seen under conditions of P+/RGD+. Interactions were
divided into those lasting less than 3 second (short duration, blue bars) and those
lasting greater than 3 seconds, including stable binding (long-duration, red-bars). All
conditions which involved blocking with anti-p-selectin (P-) resulted in a significant
decrease in both short and long duration interactions (**, p < 0.01); Blocking only
RGD (RGD-) resulted in a significant decrease in long-duration interactions (*, p <
0.05) but no change in short-duration interactions.
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Monocyte exposure to P-selectin results in downstream monocyte integrin-activation
Integrin receptors, in their open conformation, are known to interact with RGDcontaining ligands [48]. Using an antibody that recognizes an epitope exposed only
when the 1 integrin is in its open conformation, we assessed the conformation of
monocyte integrins before and after flow through the ECP model. Figure 6 shows that
as the number of short-acting monocyte-platelet interactions increased, there was
corresponding increase in the percentage of monocytes expressing integrins in their
open conformation immediately post-flow. The blue line shows that an average of
71% of monocytes which had received a high number of platelet-interactions (> 61+ 19
/lpf x sec) expressed 1 in the active form, in comparison to 9% monocytes which
received a low number of platelet interactions (< 5.1 + 2 /lpf x sec). These results were
not significantly affected by pre-treating the adherent platelets with an irrelevant
isotype control (red line). In contrast, pre-treating platelets with anti-p-selectin reduced
the platelet-monocyte interactions to near zero, and monocytes emerging from flow in
these conditions (green line) displayed low levels of active 1 integrins, irrespective of
the density of platelets to which they were exposed. It is noteworthy that all cell
populations prior to passage through the plates demonstrated similar low levels (data
not shown) of baseline integrin activation; therefore, differences seen in short-duration
monocyte-platelet interactions were not the result of differences in integrin
conformation pre-flow.
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Figure 6. Effect of p-selectin exposure on monocyte intergrins. Plastic plates were
coated with platelets at the relative density indicated by the x-axis. Platelets were then
pretreated with anti p-selectin (green line) or an isotype control (red line), or received
no pretretment (blue). Monocytes were passed through the plates at 0.5 dyne/cm2 and
then immediately assessed by flowcytometry for expression of active 1 integrins. The
y-axis indicates the percent of monocyte which bound an antibody directed at an
epitope only exposed when the integrin is in the open confirmation.

Monocyte exposure to P-selectin required for DC differentiation
Given the dependence of platelet-monocyte interactions on platelet p-selectin, we set
out to determine if there was a relationship between monocyte exposure to p-selectin at
time 0, and the phenotype later developed by the monocyte after overnight incubation,
time 18-hours (Figure 7).

Monocytes were passed though parallel plates coated with

high densities (108 + 36/lpf) of platelets that were either untreated (unblocked), or
pretreated with either anti-p-selectin or an isotype control. On average, 15.5 + 4 % of
monocytes exposed to unblocked platelets became membrane HLA-DR+/CD83+
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(markers of maturing DC) after overnight incubation, and 13 + 4 % of the those
exposed to platelets blocked with the irrelevant isotype control. In stark contrast, only
3 + 2% of the those monocytes exposed to platelets blocked with anti-p-selectin
became HLA-DR+/CD83+ after overnight incubation.

Figure 7. Effect of p-selectin exposure on monocyte phenotype after overnight
incubation. Platelet-coated plates were either untreated (first column), or pretreated
with an isoptype control (second column) or anti p-selectin (third column). Monocytes
were passed through the plates at 0.5 dyne/cm2 then incubated overnight. The y-axis
indicates the percent of monocytes which developed a phenotype consistent with DC
differentiation, membrane HLA-DR+/CD83+.
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Enhancement of ECP’s DC-generating capacity
Since our data indicate that platelets induce monocyte-to-DC differentiation, the
following changes were incorporated into the traditional clinical ECP system to
maximize monocyte interactions with platelets:
First, experiments and mathematical calculations determined that the optimal
volumetric flow rate for maximizing monocyte-platelet interactions in the ECP
apparatus was 24 ml/min (as opposed to currently used clinical value of 100 ml/min).
Details pertaining to this determination can be found in Appendix A. Briefly, this value
was determined by (1) experimental evidence that monocyte-platelet interactions
preferentially occur at wall shear stress between 0.4-0.6, and (2) correcting for the
dependence of cell flux on flow rate (see Appendix A).
Second, clinical ECP exposure plates were pre-coated with platelets.
Third, a “wash-out” step, in which elevated shear forces were applied to disassociate
any platelet-attached monocytes, was applied for approximately 30 seconds at the
conclusion of the ECP procedure.
Fourth, since the previously described interactions with platelets are independent of
UVA energy, and indeed, all the previously described results using the model were
carried out in the absence of both 8-MOP and UVA, we simplified the clinical ECP
system by eliminating the use of 8-MOP and UVA energy.
Using this enhanced ECP system, 50.5 + 11 % of the treated monocyte population was
found to enter the DC pathway as determined by measuring the membrane expression
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of HLA-DR and cytoplasmic CD83, compared with 30.0 + 6% in traditional ECP, and
5.25 + 2% of the non-treated control (Figure 8).

Figure 8. Enhancement of traditional ECP. The traditional ECP system was modified
based on principles presented in this thesis to maximize platelet-monocyte interactions:
(1) flow rate was changed from 100 ml/min to 24 ml/min; (2) exposure plate was precoated with platelet rich plasma; (3) theoretically adherent cells were “washed out”
with application of high shear stresses at the conclusion of treatment; (4) the use of 8MOP and UVA energy was discontinued. Each of the three conditions on the x-axis
were conducted side-by-side using samples obtained from the same subject, repeated
and averaged for 4 subjects. Control samples did not receive exposure to the ECP
apparatus, but underwent the identical preparation steps which treated samples
received.
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DISCUSSION
Our collective data reveal that platelets substantially contribute to signaling the
induction of monocyte-to-DC differentiation. By providing a setting in which ample
monocyte-platelet interactions may occur, ECP may be co-opting and enhancing a
natural physiologic mechanism for DC generation. The rapidity and efficiency of this
cellular conversion, in the absence of exogenously added growth factors and without
the need for lengthy tissue culture, are consistent with the timeframe and conditions
normally operative in vivo in the initiation of DC responses.
Previous studies on ECP had revealed that the procedure causes large scale conversion
of passaged blood monocytes into leukocytes with features typical of DC, in terms of:
genetic expression, phenotype, and functional capabilities [1, 49]. This generation of
DC, cells known to orchestrate the body’s immune response, may be responsible for
the therapy’s clinical effectiveness. A lack of mechanistic knowledge regarding how
ECP induced DC-differentiation has precluded introduction of scientifically-based
modifications. Enhancement of the therapy could potentially expand its therapeutic
scope to encompass a much broader range of cancers beyond CTCL.
Our results are consistent with the following mechanistic steps, in terms of DC
generation, taking place in ECP (see Figure 9, pg 44): (1) plasma fibrinogen first coats
the plastic surface of the flow chamber; (2) through its IIb3 receptor, unactivated
platelets bind and adhere to the plastic-immobilized fibrinogen; (3) platelets become
activated and instantaneously express preformed p-selectin; (4) passaged monocytes
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transiently bind p-selectin via PSGL-1, causing partial monocyte activation and
integrin receptor conformational changes; (5) partially-activated monocytes, now
capable of further interactions, bind additional platelet-expressed ligands, including
those containing RGD domains; (6) finally, so influenced, monocytes efficiently enter
the DC maturational pathway.
The above mechanism is in agreement with both our results as well as known
physiologic interactions reported elsewhere. For instance, physiologically, healthy
endothelium acts as an inhibitor of platelet adhesion [50, 51]; since ECP involves
platelet-flow in the absence of this inhibition, it is reasonable to expect that platelets
would adhere and activate upon contact with the ECP plate’s surface, as we have
observed.
Platelet activation is a critical step, as it opens the possibility of a number of monocyteplatelet interactions taking place within the ECP apparatus. Upon platelet activation,
intracellular alpha and delta granules containing preformed proteins are translocated to
the plasma membrane, and along with other mechanisms, result in the increased
expression and/or secretion of an array of proteins capable of interacting with
monocytes [52]. These proteins include: p-selectin, fibronectin, fibrinogen, CD40L,
TNF Superfamily 14, TREM-1 ligand, IGF-1, platelet derived growth factor (PDGF),
platelet factor 4 (PF4), TGF-, thrombospondin, RANTES, and CXCL10.
In order for monocytes to receive the majority of these signals from the platelet, the
monocyte must be partially activated, that is, they must have the suitable receptors
expressed in the correct “open” conformation. One ligand constitutively expressed by
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monocytes is PSGL-1, a proteoglycan capable of interacting with P-selectin expressed
by activated platelets [53]. Our findings show that monocyte binding to platelet pselectin resulted in monocyte integrin conformational changes, thereby allowing the
monocyte to receive additional signals from the platelet downstream. Furthermore,
blocking p-selectin resulted in a complete attenuation of monocyte to DC
differentiation. Other studies have reported that the PSGL-1:p-selectin interaction
results in increased expression and activation of the 41 and M2 integrins [24, 25],
NFB activity [54], TNF- secretion [54], Tissue Factor expression [55, 56], MCP-1
secretion [54, 57], and increased chemokine synthesis [58].
Downstream of p-selectin, platelet ligands containing RGD domains are likely
involved in interactions with monocytes. Our results indicate that blocking RGD
binding-sites results in a significant decrease in the long-duration monocyte-platelet
interactions. Proteins such as fibrinogen and fibronectin contain RGD domains and are
expressed by activated platelets at a high density. Monocyte integrins 51, M2,
V3, V1, and others are capable of binding RGD domains, with fibronectin and
fibrinogen serving as principle ligands for 51 and M2, respectively [48]. Integrin
signaling is well known to affect gene expression, cell growth, activation, and survival
[59].
In addition to RGD-containing proteins, other possible platelet interactions that could
contribute to DC induction include CD40L with monocyte CD40. CD40L has been
previously shown to serve as a potent activator of monocytes, and under the right
conditions, its role appears to be equivalent to that of LPS [28, 32-34]. TNF
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superfamily 14, expressed by activated platelets, has been shown to interact with
monocytes and induce proinflammatory cytokine profiles, as well as cause partial DC
maturation in certain settings [35-37]. TREM-1, a ligand on monocytes, is known to
play a large role in LPS-induced inflammation [32, 38]; interestingly, the ligand can
also engage TREM-1L expressed by activated platelets [60]. PDGF, PF4, TGF-,
RANTES, and other platelet derived products have all also been shown to induce proinflammatory changes in monocytes [40-44]. Additional studies will be required to
clarify the potential importance of these and/or other platelet ligands in facilitating
monocyte-to-DC differentiation.
The clinical success of the ECP system may very well lie in its ability to provide an in
vitro environment for monocyte-platelet interactions to take place. Removing platelets
from the confines of the endothelium places them in a pro-adhesive state in which they
readily become activated. Furthermore, the flow component of ECP provides the
natural shear forces necessary for platelet-monocyte bond formation to form. Without
shear forces, bonds that evolved to form in flowing arteries and capillaries are less
energetically favorable and unlikely to form [44, 45]. We found that activated platelets
alone, without flow, were not sufficient to cause DC differentiation.
The rapidity and efficiency with which this induction occurs suggests a physiologic
role for the mechanism. Why platelets, well known for their roles in hemostasis and
thrombosis, may have evolved to play a DC-inducing role can only be speculated. It
should be pointed out though, that at both the cellular and molecular levels, many
similarities exist between inflammation and thrombosis. For instance, inflammation
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leads to an imbalance of procoagulant to anticoagulant properties of the local
endothelium, leading to platelet accumulation and activation [31-33]. Furthermore,
platelets, due to the physical forces of flow and the phenomenon of radial dispersion,
circulate in blood at a radial position closer to the endothelium than any white blood
cell [61]. In this sense, platelets can be viewed as surveying endothelium for signs of
chronic infection/inflammation.

From this position, we propose that platelets are

ideal for recruiting and activating a few monocytes to enter the tissue and differentiate
to APC that can orchestrate the immune system’s adaptive response. This pivotal role
of the platelet would only add to the relatively recent body of literature placing it as a
central player in numerous inflammatory processes [62-65].
The implications for potentially exploiting the mechanism described in this manuscript
are tremendous. It may be possible with future advancements to generate DC for
treatment of other hematologic malignancies beyond CTCL, as well as solid tumors.
Furthermore, the ease with which this mechanism produces DC raises the possibility
that ECP could become an attractive source of DC for other experimental protocols.
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Figure 9. Proposed mechanism for induction of monocyte-to-DC differentiation.
Based on data presented in this thesis, the following sequence of events are postulated:
(1) plasma fibrinogen coats the plastic surface of the flow chamber; (2) through its
IIb3 receptor, unactivated platelets bind to the gamma-component of immobilized
fibrinogen; (3) platelets become activated and instantaneously express preformed pselectin and other proteins; (4) passaged monocytes transiently bind p-selectin via
PSGL-1, causing partial monocyte activation and integrin receptor conformational
changes; (5) partially-activated monocytes, now capable of further interactions, bind
additional platelet-expressed ligands, including those containing RGD domains; (6)
finally, so influenced, monocytes efficiently enter the DC maturational pathway within
18 hours. Note that step (1) above may be replaced physiologically by inflammatory
signals from tissue acting on local endothelium, causing it to recruit and activate
platelets in a similar manner (see text).
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SUPPLEMENTS

Please see attached CD-ROM for access to the following supplemental material:

Supplement 1: video, initial studies using ECP model
Supplement 2: video, effect of platelet density on monocytes
Supplement 3: video, effect of anti-p-selectin on monocyte interaction with platelets
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APPENDIX A
Mathematics Governing the Flow Dynamics of Extracorporeal
Photochemotherapy

Overview
Initially developed as a means of exposing T-cells to specific titratable doses of UVA
energy, the development of ECP coincidentally generated a system which subjected
human cells to complex flow dynamics. An in-depth understanding of the
mathematics governing the flow dynamics in ECP is therefore central to the
development and testing of any hypothesis involving cellular interactions occurring
within the ECP apparatus.
Principles key to understanding flow dynamics in ECP are derived and presented for
the first time in this section, along with descriptions of how, in theory, certain easily
modified ECP parameters can influence this dynamic system at the mathematical level.
Mathematically Modeling ECP

Figure A1. Therakos ECP plate.
The ECP exposure plate used clinically by the Therakos System is shown above.
During a clinical ECP procedure, cells taken from the patient are repeatedly cycled
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through this plate, which holds approximately 70 ml of fluid at a given time point. The
plate can be described as consisting of 7 linear segments measuring 25cm (length) by
3.0 cm (width) by 0.1 cm (depth), connected by 6 regions containing a curvature of
approximately 0.33 cm-1 (note: curvature is equal to approximately the inverse of the
radius, as measured from the center of the channel). Using a Cartesian coordinate
system, from this point forward this text will refer to the direction of flow as occurring
in the x-direction; the z-axis existing perpendicular to the x-axis and the two greatest
surfaces of the plate, and the y-axis existing perpendicular to both x and z as defined
above.
As with any system involving fluids, flow will occur down a potential energy gradient
as long as resistance is finite. In the case of ECP, this potential energy gradient is
generated by a peristaltic pump, which for simplicity will be modeled as generating a
driving force which does not vary with time.
Although the potential energy difference (i.e. driving force) is the same for all
molecules, it can be hypothesized that not all molecules in flow will develop the same
velocity in the steady state. Solvent molecules interact with each other through Hbonds and Van dar waals forces. The pressure difference generated by the pump in the
x-direction essentially leads to a force on the molecules which opposes the intersolvent forces. If the force generated by the pressure difference is greater than that of
adhesion, rows of molecules will accelerate in the x-direction. The force generated by
the pressure difference will be the same on all molecules regardless of its y-coordinate,
therefore all rows of molecules will be subjected to the same profile of forces relative
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to its neighbors, and therefore each row should develop the same acceleration and
velocity relative to its neighbors. As Figure A2 illustrates, the equal relative velocities
of one row with respect to its neighboring row generates an interesting velocity profile
with respect to a common, stationary point of reference: the velocity of molecules
relative to this stationary point increase as the number of rows separating the stationary
point and molecule of interest increases. In the hypothetical situation depicted in
Figure A2, the pressure difference generated by the ECP pump results in one row
overcoming inter-molecular forces to a degree that allows it to move past its
neighboring row at a velocity of 2 x-units per second. These small displacements add
up, such that relative to the stationary wall, a molecule just 8 rows away will be
moving at velocity of 16 x-units per second.
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Figure A2. Velocity increases as distance from wall increases.

To describe the phenomena explained above and other parameters of flow in useful
quantitative terms, we look to the Navier-Stokes equations for help in the derivation of
parameters particular to the ECP system we are studying. Navier-Stokes equations are
non-linear partial differential equations that arise from applying Newton’s second law
of motion to fluids; the equations describe fluid motion, and are particularly useful in
the case of one-dimensional flow. Their derivation has been described elsewhere [66]
and are shown below

51

  ( u )  ( v)


0
t
x
y
 ( u )  ( u 2  p)  ( uv) xx xy




t
x
y
x y
 ( v)  ( uv)  ( v 2 ) xy yy




t
x
y
x y
T
T
u 2  v2
 (k )  (k )
 ( e  
)
 ( uh 0 )  ( vh0 )
 (uxx  vxy )  (uxy  vyy )
y
x 
2





t
x
y
x
y
x
y
In the above equations:  = density; u and v = the Cartesian components of velocity
along the x and y axes, respectively; p = pressure; T=temperature; t=time; e = specific
internal energy (= internal energy per unit mass of fluid = CvT, where Cv is the
specific heat at constant temperature); ho = specific total enthalpy (= total enthalpy per
unit mass). Additionally, the stresses due to viscosity above, txx, txy, and tyy, are related
to velocity by the Stokes Relations:
















xx  2 ux  23   ux  yv 
yy  2 yv  23   ux  yv 
















xy    uy  vx 
yx    uy  vx 
Because of the nonlinear nature of the Navier-Stokes equations, exact solutions are
difficult to obtain. In the case of applicability to ECP, high level of simplification can
be applied to move towards exact solutions. First, we can assume that a steady state is
reached which involves fully developed flow, and therefore all time derivatives in the
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above equations can be removed. Second, we assume that viscosity remains constant
throughout the experiments.
Third, and most importantly: as described above, the Therakos ECP plate consists of 7
linear segments connected by 6 segments with significant curvature. If we elect to only
model the centers of the linear segments, far enough from the segments of curvature to
assume developed flow, then Newtonian laminar flow can be assumed. In these
conditions, flow occurs only in the x-direction, dropping all velocity components from
the y and z-directions for the above Naiver-Stokes equations. Furthermore, since the
cross-sectional dimension of linear segments, 30 mm by 1 mm, consists of a
significantly greater width than depth, we assume that fluid segments behave as if the
z-dimension is infinite, an assumption that only breaks down at the extremes of z.
With these assumptions applied to the Naiver-Stokes equations, we obtain the
following equations:

u
x
p
x
p
y
p
z

0


d 2u
dy 2

  g
0

Integrating the second equation above twice with respect to y, and treating dp/dx as a
constant with respect to y (as revealed by integrating the third equation above), yields:

u

1 p 2
y  c1 y  c2
2 x
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Defining y = 0 to be the point equidistant from both plates, and defining 2h as the total
distance between plates, and assuming u = 0 at y = +/- h, the coefficients for the above
equation are determined to be:
c1  0
c2  

h 2 p
2 x

Putting everything together, the velocity profile can be expressed as:

u

1 p 2
h  y2
2 x





Examination of the above equation reveals that velocity is dependent on the negative
square of distance from the center of the flow stream, as depicted for clarity in Figure
A3. This variation is consistent with that predicted conceptually in the previous
section and outlined back in Figure A2.

Figure A3. Velocity dependence on y-position
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While these descriptions are helpful in understanding flow occurring in ECP, by
defining a few additional parameters, these findings can be extended to help describe
the complex interactions occurring between the cellular components of ECP.
Shear rate is simply the difference in velocity of one fluid layer in relation to its
adjacent fluid layer, represented graphically by Figure A4, and mathematically by the
subsequent equation.

Figure A4. Sheer Rate in the x direction

Shear Rate = (γ) 

v2  v1 dvx

dy
dy

While we know the peristaltic pump in ECP generates a force driving one layer past
another, Newton’s second law, F=Ma, indicates that the net force must be equal to zero
if the fluid is to travel at a constant velocity as it does in ECP. Therefore, an opposing
force or source of energy dissipation must exist. This phenomenon is called shear
stress,, and is due to molecular collisions occurring between adjacent layers. These
non-elastic molecular collisions result in transfer of momentum. As can be visualized
conceptually, shear stress is therefore proportional to the number of collisions
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occurring per unit time, which itself is dependant on the velocity difference, or shear
rate, between the two layers of fluid. Thus,

τ(y) α

dvx(y)
dy

This proportionality constant is referred to as fluid viscosity, , and is dependent on
composition of the fluid: the density or molecules, their molecular weight, their shape,
etc. After addition of this proportionality constant, and substituting in the velocity
equation worked out earlier, the shear stress can be denoted as:

 1 p 2


d
h  y 2 
2 x
   p y
τ(y)   
dy
x
As this equation shows, shear stress varies linearly with distance from the center of
flow. Figure A5 below graphically represents and compares the y-dependence of
velocity, shear rate, and shear stress.

Figure A5. Dependence of velocity, shear rate magnitude, and shear stress
magnitude on y-position
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Shear stress is a parameter of critical importance in determining what bonds can form
in flow [44]. Because of this importance, it was essential for us to be able to express
this parameter as a function of parameters more easily described, such as volumetric
flow rate, Q. In order to do this, we first recognize the conceptual association between
volumetric flow rate and the velocity equation derived earlier: volumetric flow rate is
the sum all volume elements passing through regions of size dydz, thus, we can obtain
Q simply by integrating the velocity equation derived earlier with respect to dy and dx;
this equation can then be solved for dp/dx, as follows:
1 p 2
2h 3  p 
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Substituting this value back into shear rate equation derived above, we obtain the shear
rate profile in terms of parameters easily ascertained in ECP:

τ(y) 

Q3
y
W 2h 3

Thus far the fluid described has consisted of simply one type of molecule, the solvent.
The position of particles, or in ECP’s case, white and red cells, can be ascertained by
examination of the solution’s shear rate dependence on y. Particles added to a solution
will initially be randomly distributed, however, it can be hypothesized that theoretically
once flow is initiated, particles will begin to have an increased probability of migrating
towards the center of flow, or towards y = 0. This theoretical distribution is based on
the likelihood that particles in solution will collide with each other, resulting in random
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displacements. The number of collisions per unit time at any given distance, y, from
the center of flow is dependent on the relative difference in velocity between two
adjacent layers, i.e. the shear rate. Since shear rate has been calculated in the previous
section to be highest near the walls and lowest at the center of flow, particles are at a
greater likelihood to collide and undergo random displacements when in the periphery;
should a random displacement place the particle near the center of flow, it’s chances of
another collision will be lower than if the random displacement places it further from
the center. Thus, since the probability of receiving a random displacement is greater in
the periphery than center, the flux of particles into the center will be greater than the
flux out of the center. In other words, the conditions of flow in ECP will lead to the
tendency of particles to undergo an organized distribution towards the center of flow.
ECP involves the flow of many cell types, including red cells, monocytes,
lymphocytes, neutrophils, and platelets. These cell types have different properties such
as size, density, mass, deformability, and so forth. Since the center of the laminar flow
stream in ECP is a finite space, it is not possible for all cells to simultaneously reside
here. To theorize on which cells will preferentially occupy this preferred region, we
look to the laws of thermodynamics. It can be deduced from the laws of
thermodynamics that fluids in flow look to obtain the state of least entropy, S,
generation [67]. The classic definition of entropy change is simply the heat transferred
divided by the temperature at which that heat was transferred, integrated from the start
temperature to end temperature.
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Entropy changes can be quantified in fluids without regard to temperature changes by
tying together a sequence of logical statements. Since in the steady state, there is no
acceleration of fluid in the x direction, all work done in the x direction must be
balanced by energy dissipated by the frictional shear stress. This connects heat transfer
to the previously described shear stress, which is itself connected to the work done on
the fluid by the pump (since the energy transfers must be equal if the fluid is to remain
at the steady state). Since work = force * distance, and distance = shear rate * dx *
time, with the work of some basic algebra and integration, we can relate changes in
entropy to shear stress and shear rate cleanly with the following equation:

S 

2
  2 *


This equation allows one to see that entropy changes will be proportional to the square

of shear stress, which Figure A5 above shows to be a minimum at the center of flow
and maximum at the walls. Therefore, entropy generation will be minimal in the state
which consists of the most massive particles occupying the center of flow, where their
collisions would occur at the lowest relative velocity and results in minimal energy
transfer.
This principle is critical to understanding flow dynamics in ECP. It dictates that the
cells with the greatest probability of interaction with the plastic plate and its absorbed
proteins are those cells which are excluded from the thermodynamically preferred
center of flow. Furthermore, this principle allows one to better predict, based on
principle, the influence that changing ECP parameters may have on cellular
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interactions. For instance, with all other parameters held constant, increasing
hematocrit may paradoxically increase the number of white-cell interactions occurring
at the plate wall. This is because an increasing density of red cells would in-effect
better exclude white cells from the center of flow, pushing them to the periphery.
Additionally, with all other parameters held constant, increasing shear rate to certain
levels could decrease the number of white-cell interactions at the plastic wall for
reasons other the dependence of these interactions on shear stress. Individual red cells
are significantly smaller than lymphocytes and granulocytes, however, under low to
medium range shear rates, red cells are known to aggregate with one-another, forming
stacks of red cells known as rouleaux. These bodies are significantly greater in size
and mass compared to white cells, and therefore are energetically favorable in the
center of flow compared to white cells. When shear rates extend to beyond that of a
critical value (dependent on other variables), the intercellular interactions maintaining
these red cell formations are overcome, and the cells become individual entities. In
these conditions, white cells are larger and more massive, and therefore become the
cell more energetically favorable for occupation of the center of flow.

Enhancing ECP
As evident from the explained derivations, the above equations and concepts hold for
any flow system consisting of constant volumetric flow between parallel plates with
the z-dimension significantly larger than the y-dimension. It is therefore fairly easy to
compare results and model flow conditions in one system with another.
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In order to enhance the flow conditions of ECP to maximize platelet-monocyte
interactions, we first recognized that the number of platelet-monocyte interactions per
unit time (Itis the product of both the likelihood that a monocyte will interact with a
platelet if within binding distance (PCT), and the flux of monocytes which are placed
within a binding distance per unit time ( Qab ). PCT is a function of shear stress, as
revealed in the results section. Shear stress derived earlier can be written as a function
of only Q when y is appropriately set equal h (wall shear stress). In summary, plateletmonocyte interactions per unit time can be written as:
IT (Q)  Qab (Q)  PCT ( (Q))

PCT ( (Q)) can be obtained using the experimental data presented in the results section on
the platelet-monocyte interaction dependence on wall shear stress, extrapolated to have Q
represent the necessary flow rate in the Therakos system (using equation derived earlier).

Qab (Q) can be calculated theoretically by integrating the appropriate equations presented
earlier over a theoretical binding distance. In this manner, I T (Q) is calculated to be at a
theoretical maximum for the Therakos system when Q = 24 ml/min.
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